WO2016109823A8 - Treatment of pediatric growth hormone deficiency with human growth hormone analogues - Google Patents
Treatment of pediatric growth hormone deficiency with human growth hormone analogues Download PDFInfo
- Publication number
- WO2016109823A8 WO2016109823A8 PCT/US2015/068328 US2015068328W WO2016109823A8 WO 2016109823 A8 WO2016109823 A8 WO 2016109823A8 US 2015068328 W US2015068328 W US 2015068328W WO 2016109823 A8 WO2016109823 A8 WO 2016109823A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- growth hormone
- pediatric
- month
- treatment
- pghd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present disclosure provides a pediatric growth hormone deficiency (PGHD) therapy for pediatric subjects. In some embodiments, the therapy comprises administering to the pediatric patient with PGHD a human growth hormone -XTEN (hGH-XTEN) fusion protein in therapeutically effective doses once a month, two-times a month, three-times a month, or four-times a month, wherein the treatment continues for at least about 3 months from first administration, and wherein the pediatric patient's height velocity does not decline during the treatment. In some embodiments, methods disclosed herein achieve results that are not statistically inferior compared to the height velocity achieved with daily injections of hGH alone over the same period.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562099431P | 2015-01-02 | 2015-01-02 | |
| US62/099,431 | 2015-01-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2016109823A1 WO2016109823A1 (en) | 2016-07-07 |
| WO2016109823A8 true WO2016109823A8 (en) | 2016-10-27 |
Family
ID=56285081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2015/068328 Ceased WO2016109823A1 (en) | 2015-01-02 | 2015-12-31 | Treatment of pediatric growth hormone deficiency with human growth hormone analogues |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2016109823A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3004716C (en) | 2008-04-29 | 2022-04-12 | Ascendis Pharma Endocrinology Division A/S | Pegylated recombinant human growth hormone compounds |
| SG181648A1 (en) | 2009-12-15 | 2012-07-30 | Ascendis Pharma As | Dry growth hormone composition transiently linked to a polymer carrier |
| KR20250059541A (en) | 2014-11-18 | 2025-05-02 | 아센디스 파마 엔도크리놀로지 디비전 에이/에스 | Novel polymeric hgh prodrugs |
| PT3220892T (en) | 2014-11-21 | 2021-11-05 | Ascendis Pharma Endocrinology Div A/S | Long-acting growth hormone dosage forms |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide assembly and methods of making and using the same |
| EP3491012A4 (en) * | 2016-07-27 | 2020-07-01 | Amunix Operating Inc. | Treatment of adult growth hormone deficiency with human growth hormone analogues |
| WO2019126576A1 (en) | 2017-12-21 | 2019-06-27 | Amunix Pharmaceuticals, Inc. | Release segments and binding compositions comprising same |
| JP7524206B2 (en) | 2019-03-04 | 2024-07-29 | アセンディス ファーマ エンドクライノロジー ディヴィジョン エー／エス | Long-acting growth hormone formulation with superior efficacy to daily somatropin - Patent Application 20070123333 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015022257A8 (en) * | 2013-03-11 | 2018-01-23 | Amunix Operating Inc | treatment of pediatric growth hormone deficiency with human growth hormone analogs |
-
2015
- 2015-12-31 WO PCT/US2015/068328 patent/WO2016109823A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016109823A1 (en) | 2016-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2016109823A8 (en) | Treatment of pediatric growth hormone deficiency with human growth hormone analogues | |
| HK1216617A1 (en) | Treatment of pediatric growth hormone deficiency with human growth hormone analogues | |
| WO2009033807A3 (en) | Therapeutic uses of b-type natriuretic peptide and human growth hormone 1-43 | |
| HK1208629A1 (en) | Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency | |
| WO2009043527A3 (en) | Therapeutic use of human growth hormone 1-43 | |
| JP2016056206A5 (en) | ||
| JP2016514132A5 (en) | ||
| WO2009043476A3 (en) | Neuromedin s as a therapeutic agent | |
| WO2009033770A3 (en) | Calcitonin c-terminal flanking peptide for use as a therapeutic agent | |
| JP2016516016A5 (en) | ||
| EP3300734A3 (en) | Use of levocetirizine and montelukast in the treatment of autoimmune disorders | |
| WO2014164285A3 (en) | Use of levocetirizine and montelukast in the treatment of vasculitis | |
| WO2005081742A3 (en) | Testosterone oral dosage formulations and associated methods | |
| EP3590338A3 (en) | Medical treatments based on anamorelin | |
| EP4578461A3 (en) | Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa | |
| JOP20190019A1 (en) | Pharmaceutical Formula for Treatment of Growth Hormone Deficiency Contains Human Growth Hormone (hGH) Fusion Protein | |
| WO2009046864A3 (en) | Use of the human pancreatic polypeptide as a therapeutic agent | |
| IL274512B2 (en) | Igg stimulated remyelination of peripheral nerves | |
| RU2018132694A (en) | PHARMACEUTICAL COMPOSITION, INCLUDING RECOMBINANT HUMAN GROWTH HORMONE FOR TREATMENT OF GROWTH HORMONE DEFICIENCY | |
| PH12021550656A1 (en) | Methods for reducing the risk of diabetes in patients being treated for high cholesterol-related illnesses | |
| WO2016181225A3 (en) | Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors | |
| JP2018522881A5 (en) | ||
| MD3803G2 (en) | Method of treating hyperkinesia of children | |
| WO2016077565A3 (en) | Methods for chronic pain management and treatment using hcg | |
| MX2018013474A (en) | Carboxylic acids for early childhood application. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15876371 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 15876371 Country of ref document: EP Kind code of ref document: A1 |